Cd4-IRES-DTRGFP
Nomenclature
C57BL/6Smoc-Cd4em5(IRES-DTREGFP)Smoc
Cat. NO.
NM-KI-190121
Strain State
Repository Live
Gene Summary
Gene Symbol
Cd4
Model Description
Validation Data

Fig.1 Expression analysis of CD4 and GFP on CD3+T in blood of CD4-IRES-DTRGFP mice.
Leukocytes were collected from the blood of 9-week-old CD4-IRES-DTRGFP mice, and analyzed by flow cytometry. Most CD4+T cells (97.3%) were GFP-positive cells.

Fig.2 CD4+ T cell and various immune cell populations in peripheral blood of CD4-IRES-DTR-EGFP mice. (In collaboration with CrownBio)
C57BL/6 mice and CD4-IRES-DTR-EGFP mice were simultaneously injected with diphtheria toxin. Results showed that after injection, CD4+ T cells and Treg cells in peripheral blood of CD4-IRES-DTR-EGFP mice were gradually depleted to 0%, while the proportion of CD8+ T cells in peripheral blood relatively increased. In contrast, immune cells such as B cells, NK cells, NKT cells, and DCs exhibited similar trends in peripheral blood between CD4-IRES-DTR-EGFP mice and wild-type mice.

Fig.3 Tumor growth in CD4-IRES-DTR-EGFP heterozygous MC38 tumor-bearing mice at different time points. (In collaboration with CrownBio)
After CD4-IRES-DTR-EGFP heterozygous mice and wild-type mice were inoculated with the MC38 colon cancer cell line, diphtheria toxin was injected on day 8 and subsequently administered every two days for a total of 3 doses. Tumor growth was monitored before and after treatment.
Publications 1piece
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more